在阿尔茨海默氏病模型中,DHEC甲基酸减轻了病理和异常的N-糖基化在阿尔茨海默氏病模型中
Yue Wang1, Yiming Cao1, Hongfei Huang1
1Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Neuropharmacology
|February 7, 2024
概括
乙甲基酸 (DHEC) 甲基酸通过改善空间记忆和减少AD病理来改善阿尔茨海默病 (AD) 治疗的前景. 它通过通过AMPK和ERK信号通路纠正异常的N-糖化.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 由于目前选择的局限性,阿尔茨海默病 (AD) 治疗需要新的治疗方法.
- 作为Ergoloid mesylates的组成部分的二甲基酸 (DHEC) 甲基酸可能会降低粉样β的产生.
- 在阿尔茨海默氏症中,DHEC甲酸的治疗潜力和机制在很大程度上仍未被探索.
研究的目的:
- 在阿尔茨海默氏病模型中研究DHEC甲酸的药理作用.
- 阐明DHEC甲酸在AD中的作用的潜在分子机制.
- 评估DHEC甲基酸对认知功能和AD特异性病理的影响.
主要方法:
- 在AD模型中使用DHEC甲基酸盐.
- 空间记忆和阿尔茨海默氏症类型病理的评估.
- 对异常的两截断N-糖化模式的分析.
- 对AMPK和ERK信号通路的研究.
主要成果:
- 给予DHEC甲基酸盐缓解了空间记忆缺陷和阿尔茨海默氏症类型的病理.
- 甲酸DHEC的治疗改善了异常的两截式N-糖化,这是潜在的AD生物标志物.
- 甲甲甲酸的保护作用通过AMPK和ERK信号传递进行介导,AMPK是下游的主要通路.
结论:
- 甲甲酸DHEC证明了对阿尔茨海默病的治疗潜力.
- 该药物通过通过AMPK/ERK信号调节N-糖化来改善认知衰退和神经病理学.
- 这些发现支持DHEC甲酸作为AD的可行的治疗策略的发展.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487
Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193


